Oncolytics Biotech Inc T.ONC

Moody's report: BMS, Merck, Pfizer face steep patent cliff

[Noteable]

June 21, 2022 - Bristol Myers Squibb, Pfizer and Merck will face extreme patent cliff exposure later in this decade. But those companies also have the financial flexibility to perform mergers and acquisitions (M&A) to overcome the anticipated losses.

Those were just some of the findings from analysts at Moody’s Investors Service, who recently ranked the industry’s top 19 companies by their patent cliff exposure from 2026 to 2029 and their ability to adjust with M&A.

Pfizer has been active with acquisitions of Arena for $6.7 billion and Biohaven for $11.6 billion. The company has capacity to do more as its $31.6 billion in cash holdings (before those M&A deals) tied it with Johnson & Johnson for the most in the industry.

https://www.fiercepharma.com/pharma/bms-pfizer-merck-face-extreme-patent-exposure-all-have-financial-flexibility-ma-scores

[Noteable]

For Q2 2022 Pfizer booked revenues of  USD $27.7 Billion, an increase of USD $8.8 billion, or 47%, compared to the prior year quarter, reflecting operational growth of USD $10.1 billion, or 53% increase. The company now has the capacity to do even more as its cash holdings increased to USD $59.3 Billion (before the Arena and Biohaven M&A deals) - USD$ 41 Billion when taking into

[Noteable]

Because of the noise on this message board, its necessary to sometimes repeat what has already been stated - such as this Moody's report and PwC reporting that Big Pharma's "M&A "sweetspot" for 2022 is between USD $5 Billion to USD$ 15 Billion. [ For Q2 2022 Pfizer booked revenues of  USD $27.7 Billion, an increase of USD $8.8 billion, or 47%, compared to the